linjc16/ctgov huggingface dataset:
The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer

Study Overview
=================
Brief Summary
-----------------
This is a prospective cohort study on the effect of Andrographis Paniculata (AP) on palliative management of patients with advanced or metastatic esophageal cancer. A total of 30 patients with locally advanced or metastatic squamous esophageal cancer will be recruited for the trial.

Official Title
-----------------
The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer

Conditions
-----------------
Squamous Cell Carcinoma of Esophagus

Intervention / Treatment
-----------------
* Drug: Andrographis Paniculata


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged over 18 Locally advanced esophageal cancer with invasion or adherent to surrounding organs including trachea, recurrent laryngeal nerves and descending aorta; Presence of distant metastasis; Extensive lymph node metastasis to beyond surgical therapy Exclusion Criteria: Patients who cannot receive palliative stenting for dysphagia or under other conventional treatment including chemotherapy or chemoradiotherapy Patients who are not willing to receive Chinese herbal medicines Patients who do not consent for the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Andrographis Paniculata treatment<br>Single lot of Andrographis paniculata (AP) concentrated granules (Andrographis Herba) will be manufactured by Nong's Company Limited under GMP standard | Drug: Andrographis Paniculata<br>* AP as palliative treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptomatic relief and quality of life after AP | Symptomatic relief of Dysphagia and quality of life after treatment Dysphagia measured by Dysphagia score Quality of Life measured by EORTC-QLQ-C30 | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difficulty to swallow | Difficulty to swallow by dysphagia grade 0 = able to eat normal diet / no dysphagia. = able to swallow some solid foods = able to swallow only semi solid foods = able to swallow liquids only = unable to swallow anything / total dysphagia | 4 months | 
| Survival | Median Survival | up to 36 months | 
| Adverse events | Rate of adverse events | up to 36 months | 
| AP side effects | Side effects related to AP including Gastrointestinal upset Nausea and Vomiting Allergy Diarrhoea Abdominal pain Dizziness | 4 months |
Transition From Acute to Chronic Pain After Inguinal Hernia, Hysterectomy and Thoracotomy: Analysis of Risk Factors and Association With Genetic Polymorphisms

Study Overview
=================
Brief Summary
-----------------
The treatment of postoperative pain continues to be inadequate in the investigators practice setting. Inadequate pain treatment not only contributes to postoperative complications in the short term but can also be a factor that favors the development of chronic postoperative pain and diminishes long-term quality of life. Risk factors that can lead to a transition to chronic pain need to be analyzed.

Official Title
-----------------
Transition From Acute to Chronic Pain After Inguinal Hernia, Hysterectomy and Thoracotomy : Analysis of Risk Factors and Association With Genetic Polymorphisms

Conditions
-----------------
Chronic Postoperative Pain

Intervention / Treatment
-----------------
* Procedure: Inguinal herniorraphy.
* Procedure: Hysterectomy.
* Procedure: Thoracotomy .


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with given inform consent, aged mor than 18 years, who undergo scheduled surgery of one of the following types: inguinal hernia (men), hysterectomy, thoracotomy (men). Exclusion Criteria: Patients aged less than 18 years, Patients requiring reoperation because of surgical complications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients who had inguinal herniorraphy.<br> | Procedure: Inguinal herniorraphy.<br>* Inguinal herniorraphy (non laparoscopic).<br>|
| Patients who had hysterectomy.<br> | Procedure: Hysterectomy.<br>* Hysterectomy: Vaginal and abdominal.<br>|
| Patients who had thoracotomy.<br> | Procedure: Thoracotomy .<br>* Thoracotomy (non laparoscopic).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of chronic postsurgical pain. | After 3 months a physical examination will take place and after 12 months a follow-up will be reported by phone. | After 3 and 12 months of surgery. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Predictive factors of chronic postsurgical pain. | Preoperative (psychological factors, preoperative pain, pharmacologic treatment) intraoperative (surgical technic, type of anaestesia) and postoperative(posoperative pain, surgical complications and treatment of postoperative pain). | After 3 and 12 months of surgery. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic pain, genetic polymorphisms, postoperative pain
the Relationship Between Vertebral Body Length, Subarachnoid Space Width and Block Level

Study Overview
=================
Brief Summary
-----------------
Spinal anesthesia technology has been widely used in various surgeries and multi-mode analgesia. Spinal ultrasound imaging has been proved to be a reliable tool for evaluating spinal parameters. Ultrasound-guided spinal puncture technology has also been skillfully applied in clinical practice. How to provide perfect nerve block effect for operation, provide good postoperative analgesia, and prevent unnecessary extensive block leading to other complications and related risks has always been the focus of anesthesiologists. Doses and the relationship between the anesthesia plane great individual differences, and previous research on the patient's own condition such as height, weight, 6 to the anesthesia plane have different results, the influence of clinical work often refer patients height adjustment of drug doses, this research attempts to evaluate ultrasound was used to assess spinal vertebral body in the plane of the length and width of subarachnoid and anesthesia.

Official Title
-----------------
the Relationship Between Vertebral Body Length, Subarachnoid Space Width and Block Level

Conditions
-----------------
Combined Spinal Epidurai Anesthesia, Lower Extremity Surgery

Intervention / Treatment
-----------------
* Device: ltrasonic measure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing elective lower limbs surgery ASA: grade I to III Exclusion Criteria: There are contraindications to spinal anesthesia Allergic to local anesthetics Patient refused

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ultrasound-guided group<br>Adult patients with American Society of Anesthesiologists physical status I/II/III scheduled to undergo elective Lower limb surgery under spinal anesthesia were considered for eligibility. | Device: ltrasonic measure<br>* In the right decubitus position, the spine was scanned with an ultrasonic convex array probe. Starting from the sacrum, the length of each vertebral body of the lumbar spine was measured on a para-midsagittal oblique view. The intervertebral space was located and the width of the subarachnoid space was measured on a midsagittal and transverse view.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The length of lumbar cone | Ultrasound findings | 1year | 
| The width of subarachnoid space was measured by ultrasound | Ultrasound findings | 1year |
Additive Hemostatic Efficacy of EndoClot After EMR or ESD in the Gastrointestinal Tract

Study Overview
=================
Brief Summary
-----------------
The investigators want to verify in a randomised trial, the effectiveness of EndoClotTM in preventing post-procedural bleeding after EMR (Endoscopic Mucosal Resection) or ESD (Endoscopic Submucosal Dissection) for sessile lesions >20 mm in the right colon

Official Title
-----------------
Italian Multicenter Prospective Randomized Trial to Compare Additive Hemostatic Efficacy of EndoClot System to Prevent Bleeding After Endoscopic Mucosal Resection or Endoscopic Submucosal Dissection of Lesions in the Gastrointestinal Tract

Conditions
-----------------
Colonic Polyp, Colonic Neoplasms, Colonic Dysplasia

Intervention / Treatment
-----------------
* Procedure: EndoClot


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years old lesions suitable for EMR or ESD > 20 mm site in the right colon Exclusion Criteria: Severe cardiovascular pathologies Liver and Urinary dysfunctions Hematologic diseases Pregnancy and breast feeding impossible follow-up platelet and coagulation disorders (PLT < 50 x 109/L, INR > 2) Sensitivity or allergy to the drug

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EndoClot<br>spraying of Endoclot powder after EMR or ESD | Procedure: EndoClot<br>* All patients enrolled and submitted to EMR or ESD in several units of Italian endoscopy will be divided into two different groups: in a first group will be included patients at the endoscopic end of which will be applied EndoClotTM based on the lesion removed in addition to the treatment Standard (drug injection, electrocoagulation, metal clips). The second group, on the other hand, includes patients in whom EndoClotTM will not be used. Before the end of the procedure neither the endoscopist nor the patient will know the group because the group to which the patient is assigned will be written in a sealed envelope that will be opened only at the end of the procedure before the endoscope extraction: The use of EndoClotTM will depend on the group to which the patient belongs.<br>|
| No Intervention: control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| effectiveness of EndoClotTM in preventing post-procedural bleeding | The investigators want to verify in a randomised trial, the effectiveness of EndoClotTM in preventing post-procedural bleeding after EMR (Endoscopic Mucosal Resection) or ESD (Endoscopic Submucosal Dissection) for sessile lesions >20 mm in the right colon | 14 days |
A Novel Approach for Transmuscular Quadratus Lumborum Block

Study Overview
=================
Brief Summary
-----------------
a novel approach for TQL (anterior Q.L) block aiming mainly for terminal branches of lumbar plexus. The technique is described as Para-Spinous Saggital Shift Q.L block, done at L4 transverse process level in saggital orientation.

Detailed Description
-----------------
With this approach, we think it has advantages of easy identification, better caudal LA spread till under fascia iliaca, with the psoas major muscle provides a better protective barrier against accidental needle entry into the peritoneal cavity, the endpoint is injection within a fascial plane, rather than a specific motor response contact where the lumbar plexus stimulation is not sought, so there is minimal risk of nerve injury, inadvertent dural cuff puncture and intrathecal spread of local anesthetic. And finally optimal insertion of catheter in long axis of Q.L and psoas major if continuous analgesia is planned.

Official Title
-----------------
A Novel Approach for Transmuscular Quadratus Lumborum Block for Peri-operative Analgesia in Hip Surgery

Conditions
-----------------
Transmuscular Quadratus Lumborum Block Hip Surgery

Intervention / Treatment
-----------------
* Procedure: transmuscular quadratus lumborum block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Orthopaedic patients, American Society of Anesthesiologists (ASA) physical status I-III, scheduled to undergo unilateral hip surgery. Exclusion Criteria: History of neurological/neuromuscular, psychiatric disease, dementia preventing proper comprehension. Patients with Body Mass Index (BMI) <18.5 or >30 kg/m2. Coagulation disturbances (INR>1.4, platelet count<100 000). History of opioid dependence (opioid use within the last 4 weeks). History of allergies to study medications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TQL group<br>transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery | Procedure: transmuscular quadratus lumborum block<br>* transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| peri-operative analgesia in hip Surgery | post-operative VAS score | one month |
Determination of the Optimum Cut-off Value of Type 2 Diabetes Diagnosis Among Chinese Population(SENSIBLE STUDY II)

Study Overview
=================
Brief Summary
-----------------
Study of the correlation between AGEsP and HbA1c and diabetic retinopathy prevalence: determination of cut-off value of AGEsP and HbA1c in type 2 diabetes diagnosis in China

Detailed Description
-----------------
To find the cut-off point of AGEsP and HbA1c for diagnosis of diabetes by drawing the logistic regression model between prevalence of retinopathy and AGEsP level and HbA1c level,and find the point where the prevalence of retinopathy changes most rapidly.

Official Title
-----------------
Determination of Cut-off Value of Advanced Glycation End-product and Glycosylated Haemoglobin in Type 2 Diabetes Diagnosis in China

Conditions
-----------------
Type II Diabetes

Intervention / Treatment
-----------------
* Device: syringe, fundus camera etc


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20 70 years old; Volunteer to participate in this study and signed informed consent. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: syringe, fundus camera etc|Physical examination, fundus examination, blood and urine samples collection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of retinopathy | the prevalence of retinopathy in different AGEsP and HbA1c levels | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of retinopathy | incidence of retinopathy in different AGEsP and HbA1c levels | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glycosylated haemoglobin, advanced glycation end products
Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes

Study Overview
=================
Brief Summary
-----------------
The endothelium is the lining of the blood vessels that helps prevent damage to the vessels. The endothelium does not function as well as it should in adolescents with type 1 diabetes. This causes future diabetes complications. Adolescents with diabetes also have abnormalities of the cells that repair the endothelium. These abnormalities may be due to damage caused by intermittent hyperglycemia. This studied is designed to study whether low dose, combined Vitamin C and E supplementation improves endothelial function and repair in adolescents with type 1 diabetes.

Official Title
-----------------
Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes

Conditions
-----------------
Type 1 Diabetes Mellitus

Intervention / Treatment
-----------------
* Dietary Supplement: Vitamin C
* Dietary Supplement: Vitamin E


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children and adolescent with T1D between 8 and 15 years of age will be studied. Started on insulin therapy immediately after diagnosis. Fasting c-peptide levels must be less than 0.4 ng/ml. Hgb A1c levels greater than 8.3%. All subjects must be in good health other than having diabetes. Subjects with hypothyroidism will be allowed assuming they are on stable thyroxine replacement and have normal thyroid function tests. Females on oral contraceptives will also be eligible to participate. Exclusion Criteria: History oral hypoglycemic agent use. BMI>95th percentile Hypertension Elevated creatinine levels Microalbuminuria.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitamin C and E<br>6 weeks of daily treatment with Vitamin C and E | Dietary Supplement: Vitamin C<br>* <30 kg 250 mg 30-60 kg 500 mg >60 kg 750 mg<br>Dietary Supplement: Vitamin E<br>* <30 kg 100 IU, 30-60 kg 200 IU, >60 kg 300 IU<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endothelial function | Endothelial function will be measured before and after 6 weeks of therapy with Vitamin C and E | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endothelial progenitor cells | Endothelial progenitor cells will be measured before and after 6 weeks of Vitamin C and E therapy | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adolescents, type 1 diabetes, endothelial function, vitamin C, vitamin E
Epidemiological Study in Subjects With Vulvovaginal Candidiases

Study Overview
=================
Brief Summary
-----------------
Epidemiological study about the clinical and microbiological progress in subjects under treatment for a severe vulvovaginal candidiases episody

Official Title
-----------------
Estudio epidemiológico de la evolución clínica y microbiológica en Pacientes Tratadas Por un Episodio Agudo de Candidiasis Vulvovaginal

Conditions
-----------------
Vulvovaginal Candidiases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sexually active women between 18 and 50 years of age at time of screening With diagnosis and symptomatology of VVC Exclusion Criteria: Pregnant women Diabetes Mellitus Women witihin three months after a delivery or misbirth Women with vaginal or genital infection symptomatology other than candidiases that needs antibiotic treatment Vaginal probiotics use within last three months Undiagnosed abnormal genital hemorrhage

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women with candidiases infection<br>Women that are prescribed treatment with clotrimazole: 500 mg. and probiotics (routine clinical practice) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimate cure rate in women with severe vuvovaginal candidiases infection | Women must require antimicotic treatment plus vaginal probiotic following the habitual therapeutic standards | At 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimate recurrences | It will be consider recurrences an asymptomatic period for 7-10 days and a negative culture | At 6 months | 
| Estimate recurrences | It will be consider recurrences an asymptomatic period for 7-10 days and a negative culture | At 12 months | 
| Evaluate the link between symptomatology and negative culture |  | At 3 months | 
| Evaluate the effectiveness of probiotic treatment by physician | A gynecological exploration will be performed | At 3 months | 
| Evaluate the effectiveness of probiotic treatment by patient. A satisfaction questionnaire will be performed | The subject will be asked how long the symptoms lasted and the gravity of them | At 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Candidiases, Vaginal Infections